$650 MILLION SETTLEMENT BY THE DRUG MAKERS OF PRADAXA
New York, New York, May 28, 2014- Douglas and London is proud to announce a $650 million settlement on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa. Pradaxa, an anticoagulant prescribed to lower stroke risk among those suffering from a heart condition known as atrial fibrillation, was approved for use in the United States by the FDA in October 2010. Pradaxa, made by Boehringer Ingelheim Pharmaceuticals, Inc., is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug. Firm Partner Michael London was appointed one of the five co-lead plaintiffs’ counsel to oversee the entire litigation by Judge David R. Herndon of the U.S. District Court for the Southern District of Illinois. Click here to read more.
Pradaxa (or dabigatran etexilate mesylate) is a blood-thinning oral prescription drug designed to prevent blood clots and reduce the risk of stroke in patients with atrial fibrillation (AF) that is not caused by a heart valve problem.
Manufactured by Boehringer Ingelheim Pharmaceuticals and prescribed since October 2010, Pradaxa is under FDA investigation for its link to dangerous side effects, including increased risk of serious bleeding events, heart attack and acute coronary syndrome. Pradaxa’s deadly demise, unlike other anticoagulants, is there’s no antidote to reverse hemorrhaging while on the drug. The medication must clear the kidneys, which in some bodies can take 12 hours or longer—a bleeding event far too long to survive. In addition to hemorrhaging, Pradaxa’s reported side effects have included:
- Bleeding from the gums
- Coughing up blood
- Vomiting blood (or vomit that looks like coffee grounds)
- Frequent nose bleeds
- Unusual bruising
- Pink or brown urine
- Red or black, tarry stools
While hundreds of deaths have been associated with Pradaxa use, the drug remains on the market. Lawsuits concerning the medication’s approval process and marketing by Boehringer Ingelheim are being filed daily.